Expertise: pain, oncology, metabolic disease, and cardiovascular disease
Viva biotech has established multiple in vivo assay systems to evaluate compounds. Combined with our expertise in different disease areas, we are strategically focused on four disease models: pain, oncology, metabolic diseases (diabetes and obesity), and cardiovascular disease (hypertension)
Pain Models
Chronic constriction injury model (CCI or Bennett- Xie’s model)
Spinal nerve ligation model (SNL or Chung model)
Partial sciatic nerve injury model (PSL or Seltzer model)
Peripheral neuropathy induced by diseases (STZ, TIPN & VIPN)
Inflammatory disease-induced pain model (CFA & Zymonsan)
Oncology Xenograft Models
Ectopic Xenograft Models
Human breast cancer
Lung cancer
Human squamous cell carcinoma
Orthotopic Xenograft Models
Lung, Liver, Breast, Colon.
Metastasis: Liver, Gastric.
Human Primary Tumor Models: In collaboration with local hospitals, we are able to collect human primary tumor samples to establish the stable human primary tumor models in NOD/SCID mice for compound efficacy study. The following human primary tumor models are available for compound efficacy study:
Lung cancer
Breast cancer
Colon cancer
Liver cancer
Gastric cancer, ect.
Metabolic Disease
Diabetes & Obesity
Mouse: db/db, ob/ob,
Rat: fa/fa, DIO rat
Cardiovascular Disease (Hypertension)
Animal facilities
In-housed 5, 000 sq ft animal facility including 2,500 sq ft SPF (rodent), and 2,500 sq ft conventional (dog and rabbit) facilities.
5, 000 sq ft animal facility suitable for radio-isotope labeled DMPK studies (located in Shanghai Institute of Applied Physics, CAS)
Validation Data
1. NCI-N87 gastric carcinoma xenograft data 
2. A549, NCI-H460 lung cancer xenograft tumor model 
3. DU145, PC-3 Prostatic cancer xenograft tumor model
4. MV-4-11 Myelomonocytic Leukemia (lymphoblast)– Xenograft Model
5. MDA-MB-435s breast cancer xenograft tumor mode
6. A431 Epidermal Carcinoma Xenograft Tumor Model 
7. Hypertension
8. Pain animal data (CCI, CFA, Zymosan) 
